keyword
MENU ▼
Read by QxMD icon Read
search

chemotherapy induced nausea and vomiting

keyword
https://www.readbyqxmd.com/read/28197847/erratum-to-efficacy-and-safety-of-aprepitant-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-during-the-first-cycle-of-moderately-emetogenic-chemotherapy-in-korean-patients-with-a-broad-range-of-tumor-types
#1
Jeong Eun Kim, Joung-Soon Jang, Jae-Weon Kim, Sung Yong Lee, Chi-Heum Cho, Myung-Ah Lee, Do-Jin Kim, Myung-Ju Ahn, Kil Yeon Lee, Sun Jin Sym, Myong Choel Lim, Hun Jung, Cho Eun Kim, Kyung Wan Min
No abstract text is available yet for this article.
February 14, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28194109/delayed-chemotherapy-induced-nausea-and-vomiting-pathogenesis-incidence-and-current-management
#2
REVIEW
Bernardo L Rapoport
Even when chemotherapy-induced nausea and vomiting (CINV) can be effectively controlled in the acute phase, it may still occur in the delayed phase. Identifying at-risk patients is complex and requires consideration of clinical, personal, demographic, and behavioral factors. Delayed CINV has a significant detrimental effect on patients' daily life and is responsible for significant healthcare resource utilization. Patients who do not experience acute CINV are not necessarily exempt from delayed CINV, and healthcare professionals have been shown to underestimate the incidence of delayed CINV...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28193133/integrative-therapeutic-approaches-for-the-management-and-control-of-nausea-in-children-undergoing-cancer-treatment
#3
Tha'er G Momani, Donna L Berry
Chemotherapy-induced nausea and vomiting (CINV) continues to be a common symptom experienced by children undergoing cancer treatment despite the use of contemporary antiemetics. Integrative therapeutic approaches in addition to standard pharmacologic antiemetic regimes offer potential to control CINV. The purpose of this review was to identify current evidence on integrative therapeutic approaches for the control of CINV in children with cancer. Online search engines (PubMed, CINAHL, PsychINFO) were queried using MESH terms...
February 1, 2017: Journal of Pediatric Oncology Nursing: Official Journal of the Association of Pediatric Oncology Nurses
https://www.readbyqxmd.com/read/28191518/corticosteroids-the-oldest-agent-in-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-what-about-the-guidelines
#4
Florence Van Ryckeghem
Chemotherapy-induced nausea and vomiting (CINV) remains one of the most disturbing side effects of cancer treatment. Research in antiemetic therapy has progressed gradually since the early eighties, and the development of antiemetic agents continues. This review focuses on the current management of CINV based on the most recent guidelines, and adherence to the latter is examined more carefully. Setrons (5HT3 receptor antagonists), corticosteroids, and NK-1 receptor antagonists are the cornerstones of antiemetic therapy...
April 1, 2016: Journal of Translational Internal Medicine
https://www.readbyqxmd.com/read/28190981/the-role-of-intraperitoneal-carboplatin-as-consalidation-chemotherapy-in-women-with-ovarian-carcinoma-report-of-our-experience-and-systematic-review
#5
Azamsadat Mousavi, Mojgan Karimi-Zarchi, Nadere Behtash, Mitra Modares-Gilani, Mahnaz Mokhtari-Gorgani, Nili Mehrdad, Mitra Rouhi, Pouria Yazdian Anari
BACKGROUND: Epithelial ovarian cancer is the leading cause of death from gynecology malignancy. The aim of this study was to assess the role of intraperitoneal chemotherapy with carboplatin, as a consolidative treatment, in reducing relapse and increasing survival of patients in advanced epithelial ovarian cancers, as well as evaluation of its toxicity. METHODS: This clinical trial was conducted on 30 patients with epithelial ovarian cancer in stages II-IV in Gynecology oncology department in Valiasr University Hospital, Tehran during 2005-2010...
December 2016: International Journal of Biomedical Science: IJBS
https://www.readbyqxmd.com/read/28156661/efficacy-of-triple-antiemetic-therapy-palonosetron-dexamethasone-aprepitant-for-chemotherapy-induced-nausea-and-vomiting-in-patients-receiving-carboplatin-based-moderately-emetogenic-chemotherapy
#6
Kunihiko Kobayashi, Mitsunori Hino, Masahiro Ando, Susumu Takeuchi, Masahiro Seike, Kaoru Kubota, Akihiko Gemma
: 226 Background: Chemotherapy-induced nausea and vomiting (CINV) is a major adverse toxicity of cancer chemotherapy. Recommended treatments for prevention of CINV vary among guidelines, and optimal care for CINV caused by moderately emetogenic chemotherapy has not been established. This study assess efficacy and safety of triple antiemetic therapy consist palonosetron, dexamethasone and aprepitant for carboplatin-based chemotherapy. METHODS: Chemotherapy-naïve patients with lung cancer scheduled for a first course of a carboplatin-containing regimen formed the study cohort...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28156642/adherence-to-anti-emetic-guidelines-with-a-newly-approved-chemotherapy-agent-trifluridine-tipiracil-tas-102-a-single-institution-study
#7
Aminah Jatoi
: 221 Background: To our knowledge, no study has examined adherence to antiemetic guidelines with soon-to-be-approved or newly approved chemotherapy agents. In 2015, the Food and Drug Administration approved 18 cancer drugs, underscoring the timeliness of this topic. Here, we hypothesize that patients prescribed new drugs are at risk for poor guideline adherence, and we report on antiemetic prescribing practices and outcomes with TAS-102, a recently approved drug for metastatic colorectal cancer...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28156640/efficacy-of-rolapitant-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-cinv-in-patients-with-gastrointestinal-and-colorectal-cancers
#8
Karin Jordan, Bernardo Leon Rapoport, Ian D Schnadig, Martin Chasen, Sujata Arora, Daniel Powers, Lee Steven Schwartzberg
: 222 Background: Rolapitant (VARUBI) is a selective, long-acting neurokinin-1 receptor antagonist (RA) for the prevention of CINV. Rolapitant effectively prevented CINV in phase 3 trials of patients (pts) receiving highly or moderately emetogenic chemotherapy (HEC, MEC). While MEC and HEC regimens are commonly used to treat pts with gastrointestinal and colorectal cancers (GI/CRC), very few studies have evaluated the effectiveness of a neurokinin-1 RA regimen in these pts. We assessed the incidence of CINV and efficacy of rolapitant in a subset of pts with GI/CRC...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28156638/rolapitant-for-control-of-chemotherapy-induced-nausea-and-vomiting-cinv-in-patients-with-gynecologic-cancer
#9
Lee Steven Schwartzberg, Sujata Arora, Daniel Powers, Karin Jordan, Rudolph M Navari
: 223 Background: Rolapitant, a long-acting neurokinin-1 receptor antagonist, protected against CINV in patients receiving highly or moderately emetogenic chemotherapy (HEC or MEC). METHODS: In 3 double-blind phase 3 studies, patients were randomized to receive oral rolapitant 180 mg or placebo before administration of HEC or MEC. All patients received a 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone. In a post hoc analysis of 3 pooled studies (2 HEC and 1 MEC), we assessed the efficacy and safety of rolapitant in patients with gynecologic (ovarian, uterine, or cervical) cancer...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28156571/disparities-in-the-availability-of-and-access-to-antiemetics-recommended-by-the-international-antiemetic-guidelines-in-serbia-japan-and-nepal
#10
Ana Zilic, Bishal Gyawali
: 117 Background: Guideline-consistent antiemetic therapy requires 4 classes of antiemetics (AEs) to be available and accessible for the optimal prevention of chemotherapy induced nausea and vomiting (CINV): serotonin3 receptor antagonists (5HT3RAs), neurokinin 1 receptor antagonists (NK1RAs), dopamine receptor antagonists (DOPRAs) and dexamethasone. To evaluate disparities in the availability and accessibility of AEs recommended by the international antiemetic guidelines for the prevention of CINV inpatients treated in governmental hospitals in Nepal (low), Serbia (upper-middle) and Japan (high-income)...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28156442/effect-of-food-on-the-pharmacokinetics-of-dronabinol-oral-solution-versus-dronabinol-capsules-in-healthy-volunteers
#11
D Alexander Oh, Neha Parikh, Varun Khurana, Santosh Vetticaden
: 199 Background: Dronabinol, a pharmaceutical tetrahydrocannabinol (THC), capsule is approved for anorexia associated with weight loss in patients with AIDS and for cancer chemotherapy-induced nausea/vomiting in patients with inadequate response to conventional antiemetic therapy. Food effects on absorption and bioavailability of a new dronabinol oral solution was compared with marketed capsules. METHODS: In an open-label, single-dose, 3-period crossover study, healthy volunteers were randomized to receive dronabinol oral solution 4...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152970/factors-associated-with-toxicity-related-service-use-among-community-oncology-patients
#12
Beth Lavasseur, Philip J Stella, Paul T Adams, Lauren Swafford, JoAnn Lewis, Kari Mendelsohn-Victor, Christopher Ryan Friese
: 133 Background: Chemotherapy-associated toxicities occur often, yet sparse data are available to correlate toxicities with related service use. Toxicities may disrupt treatment, impair quality of life, and induce unplanned service use. We sought to understand the frequency and correlates of unplanned service use among patients receiving first-cycle chemotherapy at 5 community-based ambulatory oncology practices in southeast Michigan. METHODS: A prospective survey examined the dichotomous outcome of toxicity-related unplanned service use...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152883/investigating-racial-disparities-in-use-of-nk1-receptor-antagonists-to-prevent-chemotherapy-induced-nausea-and-vomiting-among-breast-cancer-patients
#13
Katherine Elizabeth Reeder-Hayes, Ethan M Basch, Leah L Zullig, Morris Weinberger, Stacie Dusetzina
: 292 Background: Chemotherapy-induced nausea and vomiting (CINV) is a major concern for cancer patients and, if uncontrolled, it can have serious implications for patients' treatment outcomes, including quality of life. Guidelines recommend the use of an NK1 receptor antagonist to prevent CINV among patients beginning chemotherapy with a high risk of causing the side effect. However, barriers to use of oral NK1s (i.e., aprepitant) exist. In many cases, patients are required to fill a prescription for aprepitant at their home pharmacy...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152695/improving-anti-emetics-in-chemotherapy-induced-nausea-and-vomiting
#14
Ron Fung, Katherine Enright
: 220 Background: Chemotherapy induced nausea and vomiting (CINV) remains one of the most feared treatment-related toxicities in cancer patients. CINV has been shown to decrease quality of life and to increase dose modifications and unplanned hospital visits. Cancer Care Ontario (CCO) and the American Society of Clinical Oncology (ASCO) updated their CINV guidelines in 2013. These changes included a reclassification of many regimens from moderate (MEC) to highly emetogenic (HEC) and a decrease in the duration of serotonin inhibitors (5HT3i)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28144884/aprepitant-for-the-treatment-of-breakthrough-chemotherapy-induced-nausea-and-vomiting-in-patients-receiving-moderately-emetogenic-chemotherapy
#15
Takako Inoue, Madoka Kimura, Junji Uchida, Kazumi Nishino, Toru Kumagai, Junko Taniguchi, Fumio Imamura
BACKGROUND: Our aim was to evaluate the efficacy of oral aprepitant in rescue treatment after the primary rescue for breakthrough chemotherapy-induced nausea and vomiting (CINV) in chemotherapy-naive patients receiving moderately emetogenic chemotherapy (MEC). METHODS: This was a single-institutional phase 2 study. Patients who had received MEC regimens and developed breakthrough CINV despite antiemetic prophylaxis without aprepitant were treated with primary rescue antiemetic treatments chosen by physicians...
January 31, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28140689/the-efficacy-of-trabectedin-in-treating-ovarian-cancer
#16
Eleonora Teplinsky, Thomas J Herzog
The majority of women with epithelial ovarian cancer present with advanced stage disease and there is a critical need for novel drugs and treatment strategies to improve outcomes. Trabectedin is a unique cytotoxic agent with a complex mechanism of action. It binds to guanines in the N2 position in the minor groove of DNA and its cytotoxicity involves DNA repair pathways and transcription regulation. Trabectedin's activity is also related to the drug-induced changes of the tumor microenvironment. It has been shown to improve progression-free survival in combination with pegylated liposomal doxorubicin in patients with platinum-sensitive relapsed ovarian cancer...
February 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28139838/rolapitant-absolute-bioavailability-and-pet-imaging-studies-in-healthy-adult-volunteers
#17
X Wang, Z Y Zhang, D Powers, J Wang, S Lu, V Kansra
Rolapitant, a selective, long-acting neurokinin-1 (NK-1) receptor antagonist, demonstrated efficacy in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly or moderately emetogenic chemotherapy. Two studies in healthy volunteers evaluated 1) absolute bioavailability and 2) NK-1 receptor occupancy of oral rolapitant. Absolute bioavailability, determined by the ratio of dose-normalized exposure following a 180-mg oral dose vs. an intravenous microdose, was approximately 100%...
January 31, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28112422/efficacy-of-olanzapine-for-the-prophylaxis-of-chemotherapy-induced-nausea-and-vomiting-a-meta-analysis
#18
Ting Yang, Qianxin Liu, Min Lu, Lingyue Ma, Ying Zhou, Yimin Cui
PURPOSE: The aim of this study is to evaluate the efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV). METHODS: Literatures were searched from PubMed, Embase, Central, as well as clinicaltrials.gov for unpublished studies. Randomized controlled trials (RCTs) evaluating the efficacy of olanzapine for the prophylaxis of CINV were included in the present study. The endpoints were the number of patients who achieved complete response (no emesis and no rescue) and no nausea in the acute, delayed and overall phases...
January 23, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28108820/prevention-of-chemotherapy-induced-nausea-the-role-of-neurokinin-1-nk1-receptor-antagonists
#19
Snežana M Bošnjak, Richard J Gralla, Lee Schwartzberg
Chemotherapy-induced nausea (CIN) has a significant negative impact on the quality of life of cancer patients. The use of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists (RAs) has reduced the risk of vomiting, but (except for palonosetron) their effect on nausea, especially delayed nausea, is limited. This article reviews the role of NK1RAs when combined with 5-HT3RA-dexamethasone in CIN prophylaxis. Aprepitant has not shown consistent superiority over a two-drug (ondansetron-dexamethasone) combination in nausea control after cisplatin- or anthracycline-cyclophosphamide (AC)-based highly emetogenic chemotherapy (HEC)...
January 20, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28101677/emesis-and-nausea-related-to-single-agent-trabectedin-in-ovarian-cancer-patients-a-sub-study-of-the-mito15-project
#20
Marilena Di Napoli, Chiara Della Pepa, Laura Arenare, Giovanni Scambia, Domenica Lorusso, Francesco Raspagliesi, Gabriella Ferrandina, Vanda Salutari, Roberto Sorio, Anna Maria Mosconi, Giorgia Mangili, Lucia Borgato, Stefano Lepori, Angela Salvino, Sandro Pignata, Sabrina Chiara Cecere
The MITO 15 was a prospective, single-arm trial, evaluating trabectedin monotherapy in patients with recurrent ovarian cancer (OC) who were BRCA mutation-carriers or had a BRCAness phenotype. It is largely reported that trabectedin may induce nausea and vomiting but the real emetogenic potential of the drug, in the different schedules, has never been fully described; furthermore, OC patients are known to have an enhanced risk of developing nausea and vomiting due to female gender, abdominal spreading of the disease, and major surgery experienced by most of them...
January 19, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
28476
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"